moderna announces from participants dosed in phase 2/3 study of covid-19 vaccine candidate in adolescents
moderna announces from participants dosed in phase 2/3 study of covid-19 vaccine candidate in adolescents
we are encouraged by the interim and primary analyses of the phase 3 cove study in adults ages 18 and above and this adolescent study will help us assess the potential safety and immunogenicity of our covid-19 vaccine candidate in this important younger age population.", "we hope we will be able to provide a safe vaccine to provide protection to adolescents so they can return to school in a normal setting. this randomized, controlled phase 2/3 study will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mrna-1273 given 28 days apart."


































)